Despite bluebird bio winning a recent FDA nod for its much-anticipated sickle cell disease gene therapy Lyfgenia, the regulatory triumph left something to be desired for the company because the agency didn’t grant a lucrative priority review voucher (PRV). That came as a surprise to bluebird, which had previously inked a deal to sell a potential PRV to Novartis for $103 million. Now, bluebird is hurrying to raise millions of dollars—through two separate avenues—to fund the launch of its new sickle cell disease gene therapy and others. In one fundraising approach, bluebird said it reached an agreement to hand over future gene therapy revenues to Alterna Capital Solutions in exchange for up-front funding. The deal covers a maximum credit of $100 million for bluebird, the company said in an SEC filing (PDF). Additionally, bluebird is working with Goldman Sachs and J.P. Morgan Securities to sell $150 million in new shares. ...
A German court has dealt the first blow against CureVac amid the company’s heated COVID-19 vaccine patent fight with fellow German mRNA specialist BioNTech. The German Federal Patent Court ruled that one of eight CureVac patents involved in the litigation is invalid, the company said in a Tuesday release. The patent in question covers a process that improves the expression of mRNA in cells, Juve Patent reports. The ruling came as a surprise to CureVac, which noted that the court in April issued a preliminary opinion in favor of the patent’s validity. Still, CureVac believes its “pioneering role in mRNA technology and continuing innovation in the field made essential contributions to safe and efficacious COVID-19 vaccines,” CEO Dr. Alexander Zehnder said in a statement. The company will “continue to defend our claim for recognition and fair compensation and will take appropriate action by appealing this decision,” Zehnder added. CureVac’s appeal ...
On December 18th, local time in Colombia, a signing ceremony was held between the Municipality of Bogotá and SINOVAC. Claudia López Hernández, Mayor of Bogota, and Weidong Yin, Chairman, President and CEO of SINOVAC, signed the cooperation agreement on behalf of the two parties for the Bogota Vaccine Plant Project and announced the official launch of BogotáBio, a joint venture company jointly funded by the two parties. The Bogotá Vaccine Factory project will promote the localized production of a variety of vaccines in Colombia as well as the research and development of new vaccines and innovations, thereby enhancing the local capacity to respond to infectious diseases and prepare for the next pandemic. The signing ceremony was attended by Colombian Foreign Minister Álvaro Leyva Durán, Chinese Ambassador to Colombia Zhu Jingyang, Colombian Deputy Minister of Trade, Industry and Tourism Quintero, and nearly 60 guests from the Colombian central government, Bogota city ...
On December 18, the start-up ceremony of the Da Vinci surgical robot was successfully held in Gansu Hospital, Affiliated Cancer Hospital of Sun Yat-sen University. This marks that the first domestic Da Vinci Xi surgical robot has officially settled in Gansu Hospital of Sun Yat-sen University Cancer Hospital, helping the construction of the national regional medical center, bringing more efficient, accurate and safer surgical treatments to the majority of patients, and marking the commercialization of the domestic Da Vinci surgical robot into the era. After the launching ceremony, the Da Vinci Xi surgical robot was formally “on duty” in the operating room of Gansu Hospital, Affiliated Cancer Hospital of Sun Yat-sen University. With the assistance of the surgical robot, Executive Director Prof. Liu Zhuowei’s team successfully performed “robot-assisted partial nephrectomy” for the patient. Prof. Liu Zhuowei introduced that the surgical robot makes the surgical incision smaller, less painful, shortens the ...
Name:MEDICA 2024 Time: Nov 11-14, 2024 Venue: Dusseldorf Exhibition Center City: Dusseldorf/ Germany Product categories: Medical equipment: medical electronic instruments, ultrasound instruments, X-ray equipment, medical optical instruments, clinical examination and analysis instruments, dental equipment and materials, hemodialysis equipment, respiratory equipment, hospital wards, operating rooms, emergency room equipment, hospital office equipment, laboratory equipment, etc. Disposable consumables: disposable medical supplies, dressings and sanitary materials, various surgical instruments, etc. Medical equipment: Medical care equipment, home health care products, physical therapy, plastic surgery technology, etc. Medical periphery: Information and communication technology, medical services and publishing. About MEDICA: The MEDICA exhibition showcases the latest medical equipment, medical supplies, medical technology and services, covering various fields such as hospital equipment, surgical equipment, medical instruments, diagnostic equipment, rehabilitation equipment, and home medical supplies. Exhibitors can showcase their latest medical equipment and services at the fair, showing the strength and technical level of their companies to ...
Time: Oct 8-10, 2024 sponsor: Informa Markets Venue:Milan International Exhibition Center City: Milan / Italy Product categories: Bulk drug: Vitamins, hormones, sulfonamides, antipyretic and analgesic drugs, tetracycline, amino acids and their derivatives, chloramphenicol, digestive system drugs, other anti-infective drugs, penicillins, aminoglycosides, lincomycin, cardiovascular system drugs, anti-parasitic diseases drugs, cephalosporins, macroliones, respiratory system drugs, central nervous system drugs, and other Western medicine raw materials. Excipients and dosage forms: excipients, flux-aids, enteric-soluble materials, antioxidants, sweeteners, permeability enhancers, preservatives, disintegrators, coating materials, surfactants, sunblocks, fragrances, filter AIDS, stabilizers, lubricants, plasticizers, solvents, flavor straighteners, colorants, clarifying agents, PH regulators. Other natural extracts: Plant extract, animal extract, traditional Chinese medicine raw materials, functional food raw materials, health products raw materials, nutrition and health products raw materials, supplements, dietary fiber, beauty cosmetics raw materials, biological product reagents: antibody, nucleic acid/protein synthesis, carrier and construction, cell biological detection, animal/plant protein/antigen/polypeptide, nucleic acid analysis, library and construction, biochemistry, standard Product/reference product, ...
Name:FIME 2024 Time: June 19-21, 2024 Official Website: https://www.fimeshow.com/en/home.html Venue: Miami Beach Convention Center City: Miami / USA Product categories: Medical equipment: laboratory supplies、operating room equipment,、medical consumables、orthopedic products、medical imaging equipment、ophthalmic equipment、therapeutic instruments and accessories、 biochemical and inspection equipment、detection、analysis and diagnosis instruments and accessories、electronic medical instruments and medical furniture. Medical supplies: auxiliary supplies for the disabled、nursing and rehabilitation instruments、monitoring instruments、plastic surgery equipment、dental equipment cleaning disinfection and sterilization products、 medical packaging、home care、cotton fabrics、medicines and nutrition and health products disposable products. About FIME: FIME is the largest medical specialty show in the southeastern United States. The feature of the exhibition is both regional and international. In addition to exhibitors and professional buyers mainly from Florida, the exhibition has attracted a large number of exhibitors and professional buyers from Latin American countries by taking advantage of the advantageous geographical location of the exhibition city adjacent to the Caribbean Sea. A large number of products and equipment are ...
A recent study published in the journal Communications Medicine discusses how smartwatches can facilitate the diagnosis of arrhythmias in children. Background Smartwatches and other wearable devices are becoming increasingly popular and allow users to constantly monitor their health, leading to their value for medical diagnosis becoming well-recognized. While the utility of these devices for adults has been widely researched, including for cardiac health monitoring and reducing the time needed to detect symptomatic rhythms, little is known about how they can be used to monitor child health indicators. Palpitations and abnormalities in cardiac rhythms are a leading cause of referrals in pediatric cardiology. However, existing non-invasive methods like patch rhythm monitors are not always effective in diagnosing arrhythmias, as symptoms often present infrequently, and children cannot wear monitors for as long as adults. Invasive methods such as implantable loop monitors (ILR) allow long-term monitoring. However, this approach may not be ideal ...
Detecting cancer in the body or monitoring it during therapy is typically a time-consuming process, often conducted in later phases when signs become obvious. Researchers engaged in cancer research are continuously seeking reliable and sensitive techniques to detect a developing tumor at a very early stage and to closely monitor the success or failure of cancer therapy. Therefore, a breakthrough in early cancer diagnosis is a significant advancement. Researchers have now achieved a breakthrough with the development of a test for early diagnosis of cancer. Researchers at the Paul Scherrer Institute (Würenlingen, Switzerland) have demonstrated that changes in the organization of the cell nucleus of certain blood cells can reliably indicate the presence of a tumor in the body. Using fluorescence microscopy, the team examined the chromatin of these blood cells – DNA packaged into a complex structure. They analyzed about 200 different characteristics, including the external texture, the packing ...
Illumina has decided against further appeals of U.S. and European antitrust litigation challenging its acquisition of liquid biopsy company Grail. Illumina expects to have terms of the divestiture set by the end of the second quarter of 2024. By FRANK VINLUAN Illumina is done fighting in the courts to keep cancer-detection company Grail. The gene-sequencing giant had previously pledged to divest Grail if it did not win either the U.S. or European appeals of anti-trust cases challenging the acquisition. A U.S. appeals court came down against the Federal Trade Commission’s case on Friday, but in a narrow way that hardly handed Illumina a clear victory. After reviewing the decision, Illumina said Sunday that it has decided against further litigation. The company will divest Grail. The planned divestiture is the latest step in a journey that started within Illumina. Grail began as research within the San Diego company. Grail spun out ...
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.